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Abstract
In recent years, the phenomenon of purchasing medicine 
abroad has gradually increased. In particular, it has 
resulted in major cases with great social influence, such 
as the case of “Lu Yong Selling Counterfeit Medicine”. It 
has sparked an intense debate on the legality of oversea 
purchase of medicine. Although the treatment expense 
is greatly reduced for the patients, oversea purchase of 
medicine is suspected to undermine intellectual property 
protection. Finding a balance between “inspiring 
pharmaceutical companies to innovate” and “making it 
affordable to patients” is the key to solve the problem 
of oversea purchase of medicine. Based on the analysis 
of the positive and negative effects of overseas purchase 
of medicine, this paper proposes the principle of 
“consideration of protection and antitrust”, which not only 
protects the intellectual property rights of the medicine, 
but also prevents companies from abusing intellectual 
property rights.
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1 .   L E G A L I S S U E  O N  M E D I C I N E 
PURCHASED OVERSEA 
Recently, domestic consumers have gradually increased 
their purchases of medicine abroad through traveling, 
overseas websites, and oversea procurement service. 
Among them, Chinese consumers is the largest group of 
purchasers. The purchases are generally made in India, 
Hong Kong, and other countries or regions. The State 
Food and Drug Administration has repeatedly reminded 
consumers not to buy medicines overseas due to safety 
purposes. However, the number of purchases made on 
medicine abroad has increased. The main reasons are: first, 
the approval process for new drugs in China is too long. 
The listing time of the same drug often differs by six or 
seven years between domestic and oversea. Many patients 
cannot wait that long for the drug to be listed in China; 
the second reason is the huge price gap between domestic 
and abroad, and these new drugs are not included in the 
scope of medical insurance reimbursement. While oversea 
procurement service of medicines has greatly reduced 
the cost, it has also caused controversy over its legality, 
especially by the case of “Lu Yong Selling Counterfeit 
Medicine” occurred in 2014.
1.1  Background on the Case
Lu Yong was originally a boss of a knitwear company 
in Wuxi, which was mainly engaged in foreign trade. In 
2002, Lu Yong was diagnosed with chronic myelogenous 
leukemia. This disease does not cause sudden death like 
acute leukemia. As long as the patient takes the anti-cancer 
medicine, the disease can become stabilized. This “life-
saving medicine” is an anti-cancer drug called “Glivec” 
produced by Novartis in Switzerland. This medicine can 
stabilize the condition, but it needs to be taken constantly. 
The price of this medicine is 23,500 yuan a box. A patient 
with chronic myeloid leukemia needs to take a box per 
month. The cost of medicine in addition to the cost of 
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treatment almost hollowed out Lu’s family. In June 
2004, Lu Yong accidentally learned the imitation of the 
“Glivec” anti-cancer drug produced in India, which only 
cost 4,000 yuan for a box. The comparison tests between 
the two Glivec produced in India and in Switzerland 
indicated that there was a 99.9% similarity. According 
to the Chinese law, even if these anti-cancer drugs do 
have curative effects and are indeed true medicine, they 
will be recognized as “counterfeits” since they have not 
obtained the sales license for Chinese imported drugs. 
On March 19, 2014, Lu Yong was released on bail for the 
pending trial. On July 21, the Qijiang City Procuratorate 
filed a public prosecution against Lu Yong for the 
crime of damaging credit card management and selling 
counterfeit drugs. The court of Minjiang City in Hunan 
Province was originally scheduled to open on November 
28, 2014. He applied to extend the court opening due to 
health conditions. On January 27, 2015, the Qijiang City 
Procuratorate requested the court to withdraw the lawsuit, 
and the court made a ruling on the “withdrawal of the 
lawsuit” on the same day.
1.2  Legal Issue of the Case
The procuratorate and the court were facing a dilemma 
in this case. From the perspective of human rights, 
Lu Yong should be granted medicine after his arrest 
without violating his basic human rights; in addition, the 
procuratorate and the court must choose between the high-
priced domestic drugs or low-cost generic drugs. From 
the perspective of intellectual property protection, if the 
sales of generic drugs or overseas procurement service 
are allowed, the innovation power of pharmaceutical 
companies will be cracked down; and if they are 
prohibited, a large number of patients cannot afford the 
treatment. Proper handling of such incidents requires 
the support from the government in terms of policies, 
as well as the improvement of relevant legislation 
in a timely fashion. Of course, because of the drug 
management system in China, some domestic generic 
drug manufacturers refuse to spend much on research 
and development and are suspected of abusing market 
dominance. As a result of this, the price of drugs is too 
high, and there is a lack of innovation incentives of new 
drugs.
2.  ANALYSIS ON THE PROS AND CONS 
OF GENERIC DRUGS PURCHASED 
OVERSEA
2.1  Pros
There are four main ways to purchase Glivec and generic 
drugs for patients with chronic myelogenous leukemia in 
different countries: one is to purchase the regular medicine 
in a hospital or from a pharmacy; second is to purchase a 
generic drug produced by domestic enterprises through a 
formal route in a hospital or from a pharmacy; third is to 
purchase imported Indian generic drugs through formal 
channels in hospitals or from pharmacies; last one is to 
purchase Indian generic drugs through informal channels 
such as overseas procurement service. There is a huge 
difference in the price. Lu Yong purchased the regular 
anti-cancer drug “Glivec” imported from Switzerland 
from Chinese hospitals at a unit price of 24,000 yuan/
month. In September 2004, Lu Yong purchased generic 
drugs produced in India from Japan through individual 
oversea procurement service, and the unit price was only 
4,000 yuan/month. Later, Lu Yong directly contacted 
the Indian anti-cancer drug distributor, India Sino, to 
buy and help other patients to purchase “Glivec” generic 
drugs. Due to the large quantity of purchases, the unit 
price dropped to 200 yuan/month. The main advantages 
of medicine purchased oversea is the low price and the 
moderate quality.
2.2  Cons
The drawback of oversea purchasing of medicine 
is mainly the damage on the innovation power of 
pharmaceutical companies. Swiss pharmaceutical 
company Novartis claims that the main reason for the 
high price of patented drugs such as Glivec is because 
of the huge cost of research and development and the 
extremely low success rate. It also means that the research 
and development of Glivec took 50 years and 5 billion US 
dollars. In order to encourage pharmaceutical companies 
to develop new drugs, the United States, China and other 
countries have a 20-year patent protection period. The 
problem is that patent protection also gives monopoly 
power to pharmaceutical companies, leading to the 
emergence of “astronomical priced medicine.” In addition, 
domestic patients are exposed to risks when purchasing 
drugs overseas, such as scammers and counterfeits drugs. 
However, they are not left with many choices when their 
lives are in jeopardy. China introduced a new policy of 
“zero tariffs on anti-cancer drugs” in May, but the cost of 
medicine saved per patient is very limited, and these drugs 
are not covered by medical insurance. Thus, purchases of 
oversea medicines, especially Indian generic drugs, are 
still increasing, and it has spawned the gray interest space 
of a hundred billion yuan.
3.  THE INSTITUTIONAL CAUSE OF 
OVERSEA PROCUREMENT SERVICE OF 
MEDICINE
Patients in China and the United States have become 
the largest consumer groups for overseas purchasing 
of medicines. This has a lot to do with the legal system 
of drug patents in China, the United States and India. 
In general, China and the United States have stricter 
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intellectual property rights protection for pharmaceutical 
patents, where in India it is relatively loose. The large 
price gap in medicine is also caused by the difference in 
their intellectual property protection system.
(a) Stricter Protection Policies for Patents in the United 
States, China, and Other Countries
In 1962, the US Congress officially passed the 
“Kefauver-Harris Drug Amendment”, which greatly 
increased the approval threshold for drugs, requiring 
longer and broader clinical data (it usually takes a decade 
from research and development to clinical adoption) and 
more evaluation, even for generic drugs. This has led to 
an increase in the cost of research and development for 
pharmaceutical companies. In 1983, Bolar Company 
conducted a research trial before the expiration of a 
patent for the original drug of Roche Pharmaceuticals. 
The court ruled its results infringe. This became the last 
straw to takedown generic companies. In the second 
year, only 35% of the original patents that were expired 
were imitated, and generic companies, frightened by 
cost and supervision, voted with their feet. More than 
150 original drugs were not imitated after the expiration 
of their patents. During the 1980s, three dark clouds 
shrouded the US medical industry: high drug prices 
made medical insurance funds severely tight, low profits 
weakened pharmaceutical companies’ enthusiasm, and 
shortage of drugs caused increasing in number of deaths 
of patients. How to encourage pharmaceutical companies 
to develop “safe and effective” drugs that are affordable 
to the public? In 1984, Congressman Hatch and Waxman 
proposed the Hatch-Waxman Act, which simplified the 
original drug application process and introduced a patent 
connection system, including patent extension, market 
monopoly, and other terms improving the profitability 
of the original drug after its successful development. On 
the other hand, the bill adjusted generic drug certification 
standards, reduced the time and expense of R&D and 
market entry, and increased the probability of generic 
drugs. The FDA established a patent challenge system 
within the next few years. It allowed the generic drug 
company to challenge the patent in the patent period of 
the original drug. The first generic drug succeeded the 
challenge will have a 180-day market exclusivity (other 
generic drugs cannot be listed), and It could be sold at 
the price of 50~80% of the original drug. Since then, 
the proportion of US generic drugs in prescription drugs 
has soared from around 10% in 1981 to 86% in 2013. 
However, later, some patented pharmaceutical companies 
used complex patent law formation strategies to extend 
the life of patented drugs and to delay the use of generic 
drugs. These strategies included reverse payment (or 
“delay payment”), authorized generics, product hopping, 
bribing the rivals, monopolizing anti-cancer undeveloped 
markets, and so on. The situations in China and the United 
States are similar. The Chinese Patent Law stipulates that 
pharmaceutical formulas are patents and provide strict 
protection for drugs. Although the Chinese Patent Law 
also stipulates a “compulsory licensing system”, it has not 
been implemented in practice.
(b) More Lenient Protection Policies for Patents in 
India
The concept of “generic drugs” is not invented in 
India, but in the US, where the implementation of the 
first patent strategy taken place. The United States has 
consistently spent every effort to promote patent policies 
and to maintain and to consolidate the advantages of 
its technological powers. It constantly improves the 
patent system to meet the needs of the development 
of the country, society and the times. In 1984, about 
150 commonly used drugs in the United States had 
expired. According to the regulations at the time, if 
other manufacturers wanted to produce these drugs, they 
must apply for new patents according to the new drug 
standards. At this time, the “Hatch-Waxman Act (drug 
price competition and patent period compensation law)” 
was proposed, and the new manufacturers only needed to 
prove that their “generic drugs” products were equivalent 
to the biological activity of the original drugs. Royalties 
were unnecessary, the cost of clinical trials was reduced, 
and the application procedures were simplified. The 
average price of “generic drugs” was only 20% to 40% 
of the patented drugs, and some even differ by more than 
10 times, which greatly benefited the well-being of the 
lower classes of society. Through the ingenious use of 
regulations on generic drugs, the Indian Patent Law states 
that “the entire production techniques and procedures are 
protected, but if the techniques and procedures change, the 
corresponding product is no long subject to the original 
patent”. As a result, Indian companies have adopted 
“reverse process technology” to slightly modify the 
Western patented pharmaceutical technology, or add some 
so-called active ingredients, and obtain the patents that 
India calls “concise new drugs”, which are sold globally 
at low prices. Institutional easing has enabled the rapid 
expansion of generic drugs in India, and India has become 
a major manufacturer and supplier of low-cost, high-
quality drugs worldwide. At the end of the 20th century, 
more than 50% of Indian medicines were exported, 
becoming the world’s third largest pharmaceutical 
producer and a global drug exporter, most of which were 
generic drugs. The pharmaceutical industry has not only 
become an important factor for India’s economic growth, 
but also a better choice for poor African countries that 
cannot afford to buy expensive patented medicine. India is 
known as the “Third World Pharmacy”.
4.  MANAGEMENT OF GENERIC DRUGS 
PURCHASED OVERSEA
According to the 2017 China Cancer Registration Annual 
Report released by the National Cancer Center, China had 
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4.29 million new cancer cases and 2.81 million cancer 
deaths per year, which is equivalent to an average of 
12,000 new cancers per day and 7,700 deaths from cancer. 
As a country with a high incidence of cancer, the needs 
of national medicine for cancer treatment is enormous. 
The main drugs purchased by patients for the treatment 
of cancer are patented drugs and generic drugs. From 
the perspective of product definition, the pharmaceutical 
industry can be divided into three grades of products, 
namely, pharmaceutical patents, patented drugs and 
generic drugs. Different law enforcement methods and 
policy combinations should be adopted for different 
products.
4.1  Market of Pharmaceutical Patent Should 
Focus on Intellectual Property Protection
Pharmaceutical patents belong to the original innovation 
and should be the object of legal protection. However, 
due to the attributes of their products sharing, it is 
easy to produce problems such as “jungle of patents”. 
Therefore, the government should adopt a strategic 
combination that emphasizes intellectual property 
protection. Under the WTO framework agreement and 
the relevant TRIPS regulations, the “patent compulsory 
license” and other means should be adopted in a timely 
according to the national conditions, especially when 
patented pharmaceutical companies trying to extend their 
patent period by slightly modifying the technology. The 
biggest role of intellectual property rights protection 
is to encourage invention and creation. Inventions and 
creations require venture capital, especially for drug 
inventions. Investment of a large amount of manpower, 
material resources and capital, time, and creative labor 
is required just for the possibility to succeed. Once a 
new drug is developed, others can imitate it at will, and 
the inventor will gain nothing return. This will seriously 
diminish the inventors’ enthusiasm, and no one wants to 
actively develop new drugs. The patent system gives the 
inventors a certain right to monopolize the market for a 
certain period of time. They can be rewarded with great 
returns, not only to recover the investment in research 
and development, but also to obtain certain benefits, so 
as to continuously carry out new invention and creation 
activities. This further promotes the development of 
science and technology and the refinement of products.
4.2  Market of Patented and Generic Drug Should 
Focus on Antitrust Law Enforcement
For the market of patented drug and generic drug, the 
degree of innovation is far lower than for the market 
of pharmaceutical patent. In this area, a “consideration 
of the protection and antitrust” policy combination 
should be adopted, balancing the relationship between 
intellectual property protection and the prevention 
of intellectual property abuse. Intellectual property 
protection should have certain limits, and it shall be 
suspected of monopolistic behavior once the limits are 
exceeded. Whether it is the antitrust law in the United 
States, in the European Union, or in China, companies 
with market dominance are prohibited from using 
intellectual property rights to sell goods at unfairly high 
prices. To define the definition of an excessive pricing is 
a more complicated process, especially for intellectual 
properties. In fact, in the pharmaceutical industry and all 
other industries, antitrust law enforcement agencies rarely 
have cases of unfair and high-priced terms that resulted 
in punishing operators who abuse market dominance. So 
far, the National Development and Reform Commission 
has announced four cases of abuse of excessive market 
dominance, one of which involves the medical field. This 
implies that antitrust law enforcement agencies have not 
eased on the supervision and punishment of such abuses 
because of the difficulty in determining excessive pricing 
violations. In addition, in the patent drug market, more 
attention should be paid to the issue of administrative 
monopoly. The fair competition review system should be 
used to regulate this administrative monopoly behavior.
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